Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCI
Year: 2021
Type: article
Abstract: INTRODUCTION: Neurofilament light (NFL) reflects neuroaxonal damage and is implicated in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Little is known about NFL in pre-MCI stages, such as in individuals with objectively-defined subtle cognitive decline (Obj-SCD). METHODS: Two hundred ninety-four participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent baseline blood draw and serial neuropsychological testing over 5 years of follow-up. RESULTS: Individuals with Obj-SCD and MCI showed elevated baseline plasma NFL relative to the cognitively normal (CN) group. Across the sample, elevated NFL predicted faster rate of cognitive and functional decline. Within the Obj-SCD and MCI groups, higher NFL levels predicted faster rate of decline in memory and preclinical AD composite score compared to the CN group. DISCUSSION: Findings demonstrate the utility of plasma NFL as a biomarker of early AD-related changes, and provide support for the use of Obj-SCD criteria in clinical research to better capture subtle cognitive changes.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.12324
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: U.S. Department of Defense, U.S. Department of Veterans Affairs, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Biogen, F. Hoffmann-La Roche, Alzheimer's Disease Neuroimaging Initiative, BioClinica, Eisai, IXICO, National Institutes of Health, Genentech, National Institute on Aging, National Institute of Neurological Disorders and Stroke
Awards: G1012222616, G1032285814, G104586243, G1075639496, G1174407038, Cerebral Arterial Compliance and Cognitive Function in MCI, G1554142629, G1650819308, G1775224375, G2105457377, G2189010064, G2340207221, G2423387114, G2522063444, Cognitive Process Scores to Improve Preclinical AD Detection, G279072258, G2835601961, Re-visiting Methods for MCI Diagnosis to Improve Biomarker and Trial Findings, G29951154, G3131374986, G3146424788, G3216574877, G3553156159, G363319880, G3710456697, G3870774570, G3966393351, Identifying best methods for the detection of subtle cognitive decline, G43180419, G4501223628, G4634358690, G4673940345, G4800177743, New Quantitative Neuroimaging Metrics of Structural and Functional Connectivity of the Locus Coeruleus as a Novel Biomarker of Alzheimer's Disease Pathogenesis and Progression, G5062101045, G5207404921, G5363700876, G5654639750, G5678256514, Alzheimer's Disease Neuroimaging Initiative, Neurosciences Graduate Training Program, G6210868510, G6371410416, G6412110892, G665855531, G6719828067, Longitudinal Cognitive and Biomarker Trajectories of MCI Subtypes, G6792506723, G6804111827, G6899163935, G6948409098, G7298697282, G764699806, Intracranial arterial compliance, cerebral blood flow, and dementia risk in older adults with type 2 diabetes, G781725486, G8228018387, G8895907669, G8957659042, G9000039018, G9000122335, G9000332211, UCSD Shiley-Marcos Alzheimer's Disease Research Center P30
OpenAlex ID: W3155371527